AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD6765 for Treatment Resistant Depression
Phase 2
Completed
- Conditions
- Depression
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT00491686
- Locations
- 🇺🇸
Research Site, Rockville, Maryland, United States
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT00489853
- Locations
- 🇨🇭
Research Site, Basel, Basel Stadt, Switzerland
Interaction Between ABT-335, Rosuvastatin and Warfarin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00487136
- Locations
- 🇺🇸
Site Ref # / Investigator 5290, Little Rock, Arkansas, United States
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
Phase 3
Terminated
- Conditions
- Psychotic DisordersSchizophreniaBipolar Disorder
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00486798
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
Phase 1
Terminated
- Conditions
- Acute Myelogenous Leukemia
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00486265
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Iressa as Second Line Therapy in Advanced NSCLC-Asia
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00478049
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00477581
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00475956
- Locations
- 🇩🇪
Research Site, Herne, Ruhr, Germany
Phase 1 Pharmacokinetics of Intravenous Nexium in Children
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00474019
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
Phase 1
Terminated
- Conditions
- Advanced Solid MalignanciesAdvanced Solid TumorsCancer
- Interventions
- Drug: AZD7762Drug: Irinotecan
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00473616
- Locations
- 🇺🇸
Research site, Nashville, Tennessee, United States
🇺🇸Research Site, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath